RecruitingNot ApplicableNCT04185272

Butyrophilins Role in Colon Cancer

Role of Butyrophilins in Colon Cancers Aggressiveness Evaluation

Sponsor

Institut Paoli-Calmettes

Enrollment

200 participants

Start Date

Jun 30, 2020

Study Type

INTERVENTIONAL

Conditions

quantification of BTNL molecules in colon cancer in order to determinate if their could be used as a prognostic marquer

Min Age: 18 Years

Patient is older than 18 years old,
Signed participation consent,
Non-metastatic colon cancer immediately resectable or metastatic and liver synchronous for which it was decided a combined colic and liver surgery (metastatic patient at the outset) in multidisciplinary consultation meeting.
Performance Status (PS) 0 or 1
affiliated to the social security or beneficiary

Rectal cancer, colon cancer recurrence
Emergency of colon cancer Surgery
History of inflammatory disease of the digestive tract (Crohn's disease or ulcerative colitis)
Patient who received neoadjuvant therapy other than chemotherapy
Patient treated with immune-suppressors or long-course corticosteroids \<12 months
Pregnant women or likely to be pregnant (without effective contraception) or breastfeeding,
Person in urgent situation, person under legal protection measure, or unable to express his / her consent,
Impossibility of submitting to the medical examination of the test for geographical, social or psychological reasons

BIOLOGICALanalysis of BTN and BTNL status

analysis of BTN and BTNL expression in colon cancer and hepatic metastasis

Institut Paoli-Calmettes

Marseille, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

NCT04185272